Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a seizure drug help obese kids lose weight?

NCT ID NCT02273804

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether topiramate, a drug usually used for seizures, can help severely obese children and teenagers lose weight. 18 participants aged 9 to 17 took either topiramate or a placebo for 9 months. The main goal was to see if the drug could lower their Body Mass Index (BMI) more than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

18 people

The number who actually took part.

Started

Jun 2016

Finished

Jan 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

9 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 9-17 years old * Body Mass Index Z-score ≥ 4 SD of French reference * Weight at enrolment ≥ 50 kg * Therapeutic failure \> 6 months * For girls of childbearing age, willing to have an acceptable method of contraception (no estrogens plus progestin) * Negative pregnancy test for girls of childbearing age * Agreeing to participate upon written informed consent * Appropriate understanding of the study Exclusion Criteria: * Syndromic or secondary obesity * Major neurological or psychiatric disorder * Current or history of suicidal thought/attempts * Current or history of breakdown * Previous bariatric surgery * Severe hypercapnia * Renal dysfunction * Deformity in the urinary tract or solitary kidney * History of renal lithiasis or glaucoma * Poorly controlled diabetic children or adolescents (HbA1c \>10%) and diabetic patients treated with Metformine and/or glibenclamide * Hepatic dysfunction * Bicarbonate ≤16 mmol/L * Known hypersensitivity to the active substance or to one of the excipients * Intolerance to saccharose * Enrolment in another therapeutic study * High probability to fail to comply with treatment * Females: Pregnant, planning to become pregnant * No signature on consent form * Uncovered by the French National health Insurance system (Sécurité sociale)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obese children and adolescents are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

morbid obesity Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obese children and adolescents

Contacts and locations

Locations

  • Hopital Bicêtre

    Le Kremlin-Bicêtre, Paris, 94275, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.